Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: New and larger shareholders back SynAct's capital raise - CEO comments

SynAct Pharma

SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary general meeting, will be achieved through a combination of directed issues and a fully guaranteed rights issue. This initiative is supported by some of the company's larger shareholders and will fund the continued development of resomelagon in rheumatoid arthritis, for which the company just received EU trial approval for its phase IIb ADVANCE study.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/new-and-larger-shareholders-back-synacts-capital-raise-ceo-comments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.